CVR: 25674030
Secondary names: COPYFARM A/S, PILUM PHARMA A/S, Alternova A/S
The financial health of ORIFARM GENERICS A/S appears stable, with a notable increase in revenue from 2.07 billion DKK in 2022 to 2.46 billion DKK in 2025, reflecting a strong upward trend. Profitability has also improved, rising from 54.5 million DKK in 2022 to 77.2 million DKK in 2025, although profit margins have fluctuated. The company's equity position has seen some volatility, decreasing from 554.5 million DKK in 2024 to 496.3 million DKK in 2025, which may raise concerns regarding financial stability. Positioned within the wholesale trade of medical and hospital supplies, ORIFARM GENERICS A/S is a significant player in its industry, demonstrating resilience and growth potential despite some challenges in equity management.
AI-generated summary
Selskabets formål er at foretage salg af fortrinsvis generiske lægemidler i Danmark.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 2.5 mia. | 77.2 mio. | 1.3 mia. | 496.3 mio. | 247 | |
Compared to 288 companies in Engroshandel med læge- og hospitalsartikler
Comparison is based on industry median values
Nicki Lund Kristensen joined the board
Thomas Brandhof joined as ADM. DIR.
Karsten Haumann left as ADM. DIR.
Companies in the same industry and area
CVR 36089210
CVR 17153684
CVR 26058708
CVR 45236145
CVR 44825775
companydata.dk